{
  "schema_version": "3.1.1-production",
  "doc_id": "CT-19823",
  "evaluation_id": "CT-19823",
  "extraction_date": "2022-06-29",
  "extraction_metadata": {
    "processing_version": "auto",
    "extraction_date": "2022-06-29",
    "parser": "auto",
    "annotateur_default": "auto",
    "niveau_confiance_default": 4,
    "source_files": {
      "F1": {
        "file_name": "ct_CT-19823_BORTEZOMIB_HOSPIRA_PIS_INS_HYBR_AvisDef_CT19823.pdf",
        "type": "CT",
        "page_count": 5
      }
    }
  },
  "template_detecte": "CT_modern",
  "section_taxonomy_version": "1.0",
  "SegmentIndex": [
    {
      "segment_id": "seg_1",
      "section_label_normalise": "SYNTHESE_DE_L_AVIS",
      "section_label_brut": "L’essentiel",
      "template_detecte": "CT_modern",
      "page_start": 2,
      "page_end": 2,
      "char_start": 0,
      "char_end": 100,
      "heading_text": "L’essentiel",
      "expected_fields": [
        "smr",
        "asmr",
        "indications"
      ],
      "routing_hint": "Synthèse initiale",
      "label_confidence": 0.95
    },
    {
      "segment_id": "seg_2",
      "section_label_normalise": "INFORMATIONS_ADMINISTRATIVES",
      "section_label_brut": "Contexte",
      "template_detecte": "CT_modern",
      "page_start": 2,
      "page_end": 2,
      "char_start": 100,
      "char_end": 200,
      "heading_text": "Contexte",
      "expected_fields": [
        "type_avis",
        "produit_nom",
        "reference"
      ],
      "routing_hint": "Contexte de l'évaluation",
      "label_confidence": 0.9
    },
    {
      "segment_id": "seg_3",
      "section_label_normalise": "INDICATIONS_THERAPEUTIQUES",
      "section_label_brut": "Indications",
      "template_detecte": "CT_modern",
      "page_start": 2,
      "page_end": 3,
      "char_start": 200,
      "char_end": 400,
      "heading_text": "Indications",
      "expected_fields": [
        "indication_precise",
        "population_cible"
      ],
      "routing_hint": "Liste des indications",
      "label_confidence": 0.95
    },
    {
      "segment_id": "seg_4",
      "section_label_normalise": "COMPARATEURS_PERTINENTS",
      "section_label_brut": "Comparateurs cliniquement pertinents",
      "template_detecte": "CT_modern",
      "page_start": 3,
      "page_end": 3,
      "char_start": 400,
      "char_end": 500,
      "heading_text": "Comparateurs cliniquement pertinents",
      "expected_fields": [
        "comparateurs"
      ],
      "routing_hint": "Comparateurs référencés",
      "label_confidence": 0.9
    },
    {
      "segment_id": "seg_5",
      "section_label_normalise": "SERVICE_MEDICAL_RENDU",
      "section_label_brut": "Conclusions de la Commission",
      "template_detecte": "CT_modern",
      "page_start": 3,
      "page_end": 4,
      "char_start": 500,
      "char_end": 700,
      "heading_text": "Conclusions de la Commission",
      "expected_fields": [
        "smr",
        "asmr",
        "decision"
      ],
      "routing_hint": "SMR et décision",
      "label_confidence": 0.95
    },
    {
      "segment_id": "seg_6",
      "section_label_normalise": "AMELIORATION_SMR",
      "section_label_brut": "Amélioration du Service Médical Rendu",
      "template_detecte": "CT_modern",
      "page_start": 4,
      "page_end": 4,
      "char_start": 700,
      "char_end": 800,
      "heading_text": "Amélioration du Service Médical Rendu",
      "expected_fields": [
        "asmr"
      ],
      "routing_hint": "ASMR",
      "label_confidence": 0.95
    },
    {
      "segment_id": "seg_7",
      "section_label_normalise": "POPULATION_CIBLE",
      "section_label_brut": "Population cible",
      "template_detecte": "CT_modern",
      "page_start": 4,
      "page_end": 4,
      "char_start": 800,
      "char_end": 900,
      "heading_text": "Population cible",
      "expected_fields": [
        "population_cible"
      ],
      "routing_hint": "Population décrite",
      "label_confidence": 0.9
    },
    {
      "segment_id": "seg_8",
      "section_label_normalise": "INFORMATIONS_ADMINISTRATIVES",
      "section_label_brut": "Informations administratives et réglementaires",
      "template_detecte": "CT_modern",
      "page_start": 5,
      "page_end": 5,
      "char_start": 900,
      "char_end": 1200,
      "heading_text": "Informations administratives et réglementaires",
      "expected_fields": [
        "date_evaluation",
        "cip",
        "atc"
      ],
      "routing_hint": "Infos admin",
      "label_confidence": 0.95
    }
  ],
  "Identifiants_Produits_Liaison": [
    {
      "produit_id": "CT-19823_prod_1",
      "evaluation_id": "CT-19823",
      "nom_commercial": "BORTEZOMIB HOSPIRA",
      "dci": "bortézomib",
      "code_atc": "L01XG01",
      "code_cip13": "34009 301 668 6 4",
      "forme": "Solution injectable",
      "dosage": "2,5 mg/mL",
      "evidence": [
        {
          "field": "code_cip13",
          "f": "F1",
          "p": 5,
          "s": "34009 3",
          "t": "34009 301 668 6 4",
          "m": "manual",
          "c": 0.95
        },
        {
          "field": "code_atc",
          "f": "F1",
          "p": 5,
          "s": "Code ATC",
          "t": "L01XG01",
          "m": "manual",
          "c": 0.95
        }
      ]
    },
    {
      "produit_id": "CT-19823_prod_ref",
      "evaluation_id": "CT-19823",
      "nom_commercial": "VELCADE",
      "dci": "bortezomib",
      "code_atc": "L01XG01",
      "forme": "Poudre pour solution injectable",
      "dosage": "3,5 mg",
      "relation": "Spécialité de référence",
      "evidence": [
        {
          "field": "nom_commercial",
          "f": "F1",
          "p": 2,
          "s": "spécialité",
          "t": "VELCADE 3,5 mg, poudre pour solution injectable",
          "m": "manual",
          "c": 0.95
        }
      ]
    }
  ],
  "Evaluations_HAS": [
    {
      "evaluation_id": "CT-19823",
      "Num_avis": "CT-19823",
      "produit_nom": "BORTEZOMIB HOSPIRA 2,5 MG/ ML Solution injectable",
      "dci": "bortézomib",
      "type_avis": "Demande d'inscription sur la liste des spécialités agréées aux collectivités",
      "type_avis_enum": "Inscription",
      "forme": "Solution injectable",
      "dosage": "2,5 mg/mL",
      "indication": "Traitement du myélome multiple et du lymphome à cellules du manteau selon diverses associations",
      "classe_ATC": "L01XG01",
      "pathologie": [
        "Myélome multiple",
        "Lymphome à cellules du manteau"
      ],
      "pathologie_categorie_enum": "Hemato_oncologie",
      "maladie_rare": false,
      "ligne_traitement": "Non renseigné",
      "ligne_traitement_enum": null,
      "cim10_principal": "Non renseigné",
      "cim10_secondaires": [],
      "libelle_cim10": "Non renseigné",
      "source_cim10": "Non renseigné",
      "aire_therapeutique_niveau_1": "Antinéoplasiques",
      "aire_therapeutique_niveau_2": "Antinéoplasiques immunomodulateurs",
      "aire_therapeutique_niveau_3": "Inhibiteurs du protéasome",
      "source_aire_therapeutique": "Déduit ATC L01XG01",
      "design_etude": "Non renseigné",
      "niveau_preuve_brut": "Non renseigné",
      "niveau_preuve_interprete": "Non renseigné",
      "besoin_medical_brut": "Non renseigné",
      "besoin_medical_interprete": "Non renseigné",
      "age_restriction_flag": false,
      "age_restriction_detail": "Adultes",
      "biomarqueur_requis": "Non renseigné",
      "design_enum": "Non renseigné",
      "caractere_innovant_reconnu": false,
      "perte_de_chance_citee": false,
      "historique_Has_produit": "Référence aux avis antérieurs sur VELCADE (2016, etc.)",
      "historique_ASMR_comparateurs": "Non renseigné",
      "concurrence_therapeutique_recente": "Non renseigné",
      "vote_unanimite": null,
      "nb_votants": null,
      "nb_voix_pour": null,
      "nb_voix_contre": null,
      "nb_abstentions": null,
      "date_evaluation": "2022-06-29",
      "transcription_textuelle": "Non renseigné",
      "extraits_arguments": [],
      "gravite_patho": "Non renseigné",
      "gravite_patho_enum": [],
      "type_population_cible": "Adultes",
      "pertinence_concurrence_therapeutique": "Comparateurs cliniquement pertinents identifiés pour VELCADE",
      "evidence": [
        {
          "field": "produit_nom",
          "f": "F1",
          "p": 1,
          "s": "BORTEZOMIB",
          "t": "BORTEZOMIB HOSPIRA 2,5 MG/ ML Solution injectable",
          "m": "manual",
          "c": 0.95
        },
        {
          "field": "date_evaluation",
          "f": "F1",
          "p": 1,
          "s": "Adopté",
          "t": "Adopté par la Commission de la transparence le 29 juin 2022",
          "m": "manual",
          "c": 0.95
        },
        {
          "field": "classe_ATC",
          "f": "F1",
          "p": 5,
          "s": "Code ATC",
          "t": "L01XG01",
          "m": "manual",
          "c": 0.95
        }
      ],
      "_meta": {}
    }
  ],
  "Essais_Cliniques": [],
  "Critères_Jugement": [],
  "Tolérance": {
    "tolerance_id": "Non renseigné",
    "evaluation_id": "CT-19823",
    "essai_id": null,
    "ae_total_pct": null,
    "ae_total_pct_comparateur": null,
    "sae_pct": null,
    "sae_pct_comparateur": null,
    "discontinuations_ae_pct": null,
    "discontinuations_ae_pct_comparateur": null,
    "deaths_ae_n": null,
    "deaths_ae_n_comparateur": null,
    "sae_data_available": false,
    "sae_superieur_comparateur": null,
    "deaths_reported": false,
    "EI_graves_detailles": [],
    "EI_frequents_detailles": [],
    "ei_grade_max": "Non renseigné",
    "deces_detailles": [],
    "signal_securite_flag": false,
    "signal_securite_detailles": [],
    "signal_ansm_flag": false,
    "EI_graves": "Non renseigné",
    "EI_frequents": "Non renseigné",
    "deces": "Non renseigné",
    "signal_securite": "Non renseigné",
    "evidence": [],
    "_meta": {}
  },
  "Comparateurs_Essai": [],
  "Comparateurs_HAS": [],
  "Arguments_Decisionnels": [],
  "Données_Contexte": {
    "contexte_id": "CT-19823_ctx",
    "evaluation_id": "CT-19823",
    "ISP": "Non renseigné",
    "acces_precoce": "Aucun",
    "date_debut_acces_precoce": "Non renseigné",
    "date_fin_acces_precoce": "Non renseigné",
    "duree_acces_precoce_mois": null,
    "nombre_patients_acces_precoce": null,
    "conditions_arret_acces_precoce": "Non renseigné",
    "ISP_flag": false,
    "ISP_categorie": "Non renseigné",
    "type_acces_precoce_enum": "Aucun",
    "statut_reglementaire_ema": "AMM_standard",
    "date_AMM_ema": "2018-08-08",
    "date_avis_chmp": "Non renseigné",
    "innovation_therapeutique_ema": null,
    "designation_orpheline_ema": null,
    "prime_ema": null,
    "obligations_post_amm": [],
    "echeance_reexamen_amm": "Non renseigné",
    "nb_obligations_post_amm": null,
    "evaluation_internationale": "Non renseigné",
    "pays_evaluations": [],
    "decisions_internationales": [],
    "nb_decisions_internationales": null,
    "RDCR": "Non renseigné",
    "RDCR_num": null,
    "RDCR_intervalle": null,
    "RDCR_vs_seuil": "Non renseigné",
    "model_type": "Non renseigné",
    "perspective": "Non renseigné",
    "horizon_annees": null,
    "horizon_justification": "Non renseigné",
    "discount_rate_costs": null,
    "discount_rate_qalys": null,
    "DSA_flag": null,
    "PSA_flag": null,
    "scenario_analyses": [],
    "major_reserves": [],
    "nb_reserves_majeures": null,
    "impact_budgetaire_prevu": "Non renseigné",
    "impact_budgetaire_annee_1": null,
    "impact_budgetaire_annee_5": null,
    "impact_budgetaire_horizon": null,
    "hypothese_population_cible": null,
    "hypothese_penetration_marche_pct": null,
    "reserves_impact_budgetaire": [],
    "reserves_majeures": null,
    "population_cible_france": "Non renseigné",
    "population_cible_nombre": null,
    "population_cible_intervalle": null,
    "source_estimation_population": "Non renseigné",
    "incertitude_population": "Non renseigné",
    "population_cible_mediane": null,
    "suivi_post_inscription": false,
    "nature_suivi_post_inscription": "Non renseigné",
    "delai_suivi_mois": null,
    "delai_suivi_justification": "Non renseigné",
    "conditions_suivi": "Non renseigné",
    "echeance_suivi": "Non renseigné",
    "impact_si_non_realise": "Non renseigné",
    "delai_soumission_dossier": "Non renseigné",
    "delai_complement_demande": false,
    "dates_complement_demande": [],
    "delai_audition": false,
    "date_audition": "Non renseigné",
    "nb_total_reserves": null,
    "nb_total_reserves_mineures": null,
    "nb_totales_reserves_importantes": null,
    "nb_totales_reserves_majeures": null,
    "SMR_avant_audition_enum": "Non_renseigné",
    "SMR_apres_audition_enum": "Non_renseigné",
    "ASMR_avant_audition_enum": "Non_renseigné",
    "ASMR_après_audition_enum": "Non_renseigné",
    "type_critère_justification": "Non renseigné",
    "valeur_critère": "Non renseigné",
    "impact_décision": "Non renseigné",
    "estimation_mesure_impact": "Non renseigné",
    "evidence": [
      {
        "field": "date_AMM_ema",
        "f": "F1",
        "p": 5,
        "s": "AMM",
        "t": "08/08/2018 (procédure centralisée)",
        "m": "manual",
        "c": 0.95
      }
    ],
    "_meta": {}
  },
  "Données_Textuelles": {
    "evaluation_id": "CT-19823",
    "texte_brut": "Non renseigné",
    "embedding": null
  },
  "SMR_ASMR_Par_Indication": [
    {
      "smr_asmr_id": "CT-19823_smrasmr_1",
      "evaluation_id": "CT-19823",
      "indication_precise": "En monothérapie ou en association à la dexaméthasone, pour le traitement des patients adultes atteints de myélome multiple en progression, ayant reçu au moins 1 traitement antérieur et ayant déjà bénéficié ou étant inéligibles à une greffe de cellules souches hématopoïétiques.",
      "smr": "Important",
      "smr_enum": "Important",
      "asmr": "ASMR V",
      "asmr_enum": "V",
      "smr_revendique": "Non renseigné",
      "asmr_revendique": "Non renseigné",
      "asmr_revendique_enum": "Non_renseigné",
      "justification_decisionnelle": "Avis favorable au remboursement",
      "population_cible_indication": "Patients adultes atteints de myélome multiple en progression avec antécédents de traitement",
      "ligne_traitement_indication": "Non renseigné",
      "comparateurs_references_indication": "Non renseigné",
      "comparateur_id_HAS": null,
      "indication_structuree": {
        "ligne_traitement": "Non renseigné",
        "biomarqueur": "Aucun",
        "stade": "Progression",
        "population_age": "Adultes"
      },
      "gain_survie_cite": null,
      "qol_cite": null,
      "tolerance_acceptable": null,
      "evidence_robustesse": "Non renseigné",
      "evidence": [
        {
          "field": "smr",
          "f": "F1",
          "p": 3,
          "s": "La Commission",
          "t": "Important dans les indications suivantes : En monothérapie ou en association à la dexaméthasone...",
          "m": "manual",
          "c": 0.95
        },
        {
          "field": "asmr",
          "f": "F1",
          "p": 4,
          "s": "Amélioration",
          "t": "Cette spécialité est un médicament hybride qui n’apporte pas d’amélioration du service médical rendu (ASMR V)",
          "m": "manual",
          "c": 0.95
        }
      ]
    },
    {
      "smr_asmr_id": "CT-19823_smrasmr_2",
      "evaluation_id": "CT-19823",
      "indication_precise": "En association à la doxorubicine liposomale pégylée pour le traitement des patients adultes atteints de myélome multiple en progression, ayant reçu au moins 1 traitement antérieur et ayant déjà bénéficié ou étant inéligibles à une greffe de cellules souches hématopoïétiques.",
      "smr": "Insuffisant",
      "smr_enum": "Insuffisant",
      "asmr": "ASMR V",
      "asmr_enum": "V",
      "smr_revendique": "Non renseigné",
      "asmr_revendique": "Non renseigné",
      "asmr_revendique_enum": "Non_renseigné",
      "justification_decisionnelle": "Avis défavorable au remboursement dans cette indication",
      "population_cible_indication": "Patients adultes atteints de myélome multiple en progression avec antécédents de traitement",
      "ligne_traitement_indication": "Non renseigné",
      "comparateurs_references_indication": "Non renseigné",
      "comparateur_id_HAS": null,
      "indication_structuree": {
        "ligne_traitement": "Non renseigné",
        "biomarqueur": "Aucun",
        "stade": "Progression",
        "population_age": "Adultes"
      },
      "gain_survie_cite": null,
      "qol_cite": null,
      "tolerance_acceptable": null,
      "evidence_robustesse": "Non renseigné",
      "evidence": [
        {
          "field": "smr",
          "f": "F1",
          "p": 3,
          "s": "Insuffisant",
          "t": "Insuffisant dans l’indication : En association à la doxorubicine liposomale pégylée...",
          "m": "manual",
          "c": 0.95
        }
      ]
    }
  ],
  "Posologie_Par_Indication": [],
  "Timeline_Evenements": [
    {
      "event_id": "CT-19823_event_AMM_1",
      "evaluation_id": "CT-19823",
      "event_type": "AMM_EMA_DECISION",
      "event_date": "2018-08-08",
      "detail_brut": "AMM obtenue le 08/08/2018 (procédure centralisée)",
      "source_doc": "F1",
      "detail_type_specifique": "Non renseigné",
      "acteurs_impliques": [],
      "duree_evenement_jours": null,
      "reference_externe": "Non renseigné",
      "evidence": [
        {
          "field": "event_date",
          "f": "F1",
          "p": 5,
          "s": "AMM",
          "t": "08/08/2018 (procédure centralisée)",
          "m": "manual",
          "c": 0.95
        }
      ],
      "_meta": {}
    },
    {
      "event_id": "CT-19823_event_CT_1",
      "evaluation_id": "CT-19823",
      "event_type": "ADOPTION_CT",
      "event_date": "2022-06-29",
      "detail_brut": "Adopté par la Commission de la transparence le 29 juin 2022",
      "source_doc": "F1",
      "detail_type_specifique": "Non renseigné",
      "acteurs_impliques": [],
      "duree_evenement_jours": null,
      "reference_externe": "Non renseigné",
      "evidence": [
        {
          "field": "event_date",
          "f": "F1",
          "p": 1,
          "s": "Adopté",
          "t": "Adopté par la Commission de la transparence le 29 juin 2022",
          "m": "manual",
          "c": 0.95
        }
      ],
      "_meta": {}
    },
    {
      "event_id": "CT-19823_event_VAL_1",
      "evaluation_id": "CT-19823",
      "event_type": "AUTRE",
      "event_date": "2022-04-25",
      "detail_brut": "Date de validation administrative : 25 avril 2022",
      "source_doc": "F1",
      "detail_type_specifique": "Validation administrative",
      "acteurs_impliques": [],
      "duree_evenement_jours": null,
      "reference_externe": "Non renseigné",
      "evidence": [
        {
          "field": "event_date",
          "f": "F1",
          "p": 5,
          "s": "Date de",
          "t": "Date de validation administrative* : 25 avril 2022",
          "m": "manual",
          "c": 0.95
        }
      ],
      "_meta": {}
    }
  ],
  "Timeline_Delais": {
    "evaluation_id": "CT-19823",
    "delai_amm_ct_jours": null,
    "delai_transcription_ct_jours": null,
    "delai_audition_ct_jours": null,
    "complement_demande_mentionne": false,
    "audition_realisee": false,
    "evidence": []
  },
  "Features_Modele": {
    "evaluation_id": "CT-19823",
    "is_orphan": false,
    "classe_ATC_l2": "L01",
    "aire_therapeutique": "Antinéoplasiques",
    "type_avis_enum": "Inscription",
    "innovation_reconnue": false,
    "perte_de_chance_citee": false,
    "ligne_traitement_num": null,
    "is_rct": false,
    "n_essais": 0,
    "n_rct": 0,
    "presence_qol": false,
    "effet_principal_magnitude_num": null,
    "critere_principal_dur": false,
    "suivi_median_mois_max": null,
    "sae_pct_num": null,
    "discontinuations_pct_num": null,
    "critere_principal_description": "Non renseigné",
    "p_value_log10": null,
    "ceesp_present": false,
    "rdcr_num": null,
    "rdcr_log": null,
    "impact_budget_cat": "Non renseigné",
    "reserves_majeures": false,
    "nb_reserves_majeures": null,
    "vote_unanimite": null,
    "nb_votants": null,
    "voix_pour_pct": null,
    "association_patient_intervenue": false,
    "comparateur_placebo": false,
    "comparateur_soc": false,
    "nb_clockstops": 0,
    "annee_ct": 2022,
    "trimestre_ct": "Q2",
    "template_ere": "CT_modern",
    "missingness_indicators": "Non renseigné",
    "_meta": {}
  },
  "Relations": [],
  "Annotation_View": []
}